GlaxoSmithKline has told stock exchanges in Switzerland and the UK that it has increased its shareholding in Addex Pharmaceuticals Ltd to at least 5% of the company’s outstanding capital. The purchases were made by GSK’s investment arm, SR One Ltd, and follow earlier incremental buying in September, 2008.
JADO Technologies GmbH, a closely-held German company specialising in a new type of lipid technology, has raised €3.9 million in a series B financing led by the Berlin-based Peppermint Financial Partners.
MediGene AG is expecting to conclude a strategic partnership in 2009 for its treatment for pancreatic cancer, EndoTAG-1. The forecast is contained in the company’s financial report for the first nine months of 2008, which was issued on 7 November.
The French biopharmaceutical company, Innate Pharma SA, reported a 16% increase in revenue for the first nine months of 2008 compared with a year earlier, largely due to income from its strategic partnership with Novo Nordisk A/S.
Sanofi-aventis has stopped all clinical trials of Acomplia (rimonabant), which until recently had been sold on 32 markets around the world as a treatment for obesity. The trials were being conducted in order to investigate new indications for the drug in diabetes and heart disease.
Sygnis Pharma AG has raised about €18.3 million with new equity under a long-standing contractual agreement with its two principal shareholders, dievini Hopp BioTech holding GmbH & Co. KG and BASF SE, which will own respectively 36% and 13% of the company.
The German drug discovery and development company, 4SC AG, has restructured its drug portfolio to include oncology projects acquired from Switzerland’s Nycomed in July 2008. It is now preparing to take one of these compounds into Phase 2.
Santhera Pharmaceuticals of Switzerland has raised a gross CHF 15.9 million in a private share placement with Ares Life Sciences, an investment vehicle controlled by the Bertarelli family.
After a period of restructuring, Paion AG has started to look for partners to develop its candidate products for central nervous system and cardiovascular disorders. The German company outlined its revised business strategy in a financial report for the first nine months of 2008, issued on 5 November.
Newron Pharmaceuticals SpA has consolidated its research programme for central nervous system (CNS) disorders and pain following the takeover earlier this year of Hunter-Fleming Ltd of the UK.